DDInter122 DDInter481
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Voriconazole
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Darolutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Darolutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eslicarbazepine
Darolutamide {u} may lead to a major life threatening interaction when taken with {v} Eluxadoline
Darolutamide {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Voriconazole
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Darolutamide may lead to a major life threatening interaction when taken with Eluxadoline
Darolutamide may lead to a major life threatening interaction when taken with Berotralstat